These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36758709)

  • 21. Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy-associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1-placental growth factor ratio in the early second trimester.
    Huang T; Rashid S; Priston M; Rasasakaram E; Mak-Tam E; Gibbons C; Mei-Dan E; Bedford HM
    AJOG Glob Rep; 2023 May; 3(2):100193. PubMed ID: 37168546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of preterm birth in growth-restricted and appropriate-for-gestational-age infants using maternal PlGF and the sFlt-1/PlGF ratio-A prospective study.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    BJOG; 2024 Jul; 131(8):1089-1101. PubMed ID: 38196326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth.
    Smith GC; Crossley JA; Aitken DA; Jenkins N; Lyall F; Cameron AD; Connor JM; Dobbie R
    Obstet Gynecol; 2007 Jun; 109(6):1316-24. PubMed ID: 17540803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
    Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers at 6 weeks' gestation in the prediction of early miscarriage in pregnancy following assisted reproductive technology.
    Guo J; Feng Q; Chaemsaithong P; Appiah K; Sahota DS; Leung BW; Chung JP; Li TC; Poon LC
    Acta Obstet Gynecol Scand; 2023 Aug; 102(8):1073-1083. PubMed ID: 37377341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.
    Conroy AL; McDonald CR; Gamble JL; Olwoch P; Natureeba P; Cohan D; Kamya MR; Havlir DV; Dorsey G; Kain KC
    Am J Obstet Gynecol; 2017 Dec; 217(6):684.e1-684.e17. PubMed ID: 29031892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prognostic model to guide decision-making on timing of delivery in late preterm pre-eclampsia: the PEACOCK prospective cohort study.
    Duhig K; Seed PT; Placzek A; Sparkes J; Gill C; Brockbank A; Shennan A; Thangaratinam S; Chappell LC
    Health Technol Assess; 2021 May; 25(30):1-32. PubMed ID: 34024312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
    McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of preterm birth in women with fetal growth restriction - Is the weekly change in sFlt-1/PlGF ratio or PlGF levels useful?
    Hong J; Crawford K; Cavanagh E; Clifton V; Kumar S
    Acta Obstet Gynecol Scand; 2024 Jun; 103(6):1112-1119. PubMed ID: 38483020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
    Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
    Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal vascular-placental axis in the third trimester in women with gestational diabetes mellitus, hypertensive disorders, and unaffected pregnancies.
    Chatzakis C; Papavasiliou D; Mansukhani T; Nicolaides KH; Charakida M
    Am J Obstet Gynecol; 2024 Aug; ():. PubMed ID: 39218286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy.
    Burns LP; Potchileev S; Mueller A; Azzi M; Premkumar A; Peterson J; Rausch A; Gonzalez M; Silasi M; Karumanchi SA; Thadhani R; Rana S
    Am J Obstet Gynecol; 2024 Jul; ():. PubMed ID: 39029547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 19-23 weeks' gestation.
    Sapantzoglou I; Wright A; Arozena MG; Campos RV; Charakida M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):75-83. PubMed ID: 33142353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.